Marinus Pharmaceuticals Reports Topline Ganaxolone Phase 2 Open-Label Results in Tuberous Sclerosis Complex and Receives FDA Orphan Drug Designation
Cannabis Law Report
AUGUST 17, 2021
Food and Drug Administration (FDA) has granted orphan drug designation to ganaxolone in TSC. We look forward to initiating our Phase 3 trial and adding to the body of evidence that supports ganaxolone’s potential as an innovative treatment option for rare epilepsies.”. Conference call and webcast to be held today at 4:30 p.m.
Let's personalize your content